Boston Scientific Corporation

NYSE:BSX

Medical - Devices

Healthcare
$43.64 +1.00%

+$0.45 today

Market cap
$63.25B
Beta
0.56
P/E (TTM)
19.0
EPS (TTM)
$2.39
52W Low $44.44High $109.50

Volume 13.21M

Average 19.45M

BSX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Boston Scientific CorporationNYSE: BSX

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of $5.44B rose 7.5% year over year, behind the +13.5% change in trailing-twelve-month revenue. Sequentially, it rose 4.6% from the prior quarter. Over 3 fiscal years it compounded at +16.5% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 21 analysts of $20.97B (+4.5%) for the fiscal year ending Dec 2026, a slowdown from the +19.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.44B+4.6% QoQ
Last fiscal yearDec 2025
$20.07B+19.9% YoY
LTMJun 2026
$21B+13.5% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.5%+0.4%-7.1 pp
1 year+19.9%+4.5%-15.4 pp
3-year CAGR+16.5%+2.9%-13.7 pp
5-year CAGR+5.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
20.07B USD
Year-over-year change
+19.9%
4-year CAGR
+14.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How BSX compares with its peers on the latest reported figures

  • BSX's LTM Jun 2026 revenue of $21B is the 2nd highest of the 11 companies compared; the peer median is $1.51B.
  • Its year-over-year change of +13.5% is the 4th highest of 11, against a peer median of +11.2%.
  • Over three fiscal years its annual growth of +16.5% compares with a peer median of +9.6%.
BSX Competitors Peer median
Revenue for BSX and competitors
Company Period LTM YoY 3-year CAGR
MDTMedtronic plcLTM Jul 2026$37.54B +9.8%+5.2%
BSXBoston Scientific CorporationLTM Jun 2026$21B +13.5%+16.5%
EWEdwards Lifesciences CorporationLTM Jun 2026$6.51B +14.6%+4.1%
TFXTeleflex IncorporatedLTM Jun 2026$2.6B -14.5%-10.6%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$1.61B +9.2%+9.6%
LIVNLivaNova PLCLTM Sep 2026$1.51B +11.7%+10.8%
PENPenumbra, Inc.LTM Jun 2026$1.5B +17.6%+18.3%
CNMDCONMED CorporationLTM Mar 2026$1.37B +4.4%+9.5%
ATRCAtriCure, Inc.LTM Jun 2026$569.62M +13.9%+17.4%
ANGOAngioDynamics, Inc.LTM Feb 2026$313.73M +10.7%-2.6%
CVRXCVRx, Inc.LTM Mar 2026$59.07M +11.7%+36.1%
Peer median (excluding BSX) $1.51B+11.2%+9.6%

Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.89B12.68B14.24B16.75B20.07B
Cost of Revenue4.43B4.97B5.41B6.48B6.22B
Gross Profit7.46B7.71B8.83B10.27B13.85B
Gross Margin62.8%60.8%62.0%61.3%69.0%
Research & Development1.2B1.32B1.41B1.62B2.05B
Selling, General & Admin4.29B4.52B5.19B5.98B6.89B
Operating Expenses5.54B5.89B6.65B7.63B9.88B
Depreciation & Amortization1.09B1.14B1.2B1.27B1.37B
EBITDA2.52B2.74B3.45B3.94B5.1B
EBITDA Margin21.2%21.6%24.2%23.5%25.4%
Operating Income1.92B1.82B2.18B2.64B3.97B
Operating Margin16.2%14.4%15.3%15.7%19.8%
Interest Income4M10M22M107M0
Interest Expense349M464M272M387M349M
Other Income / Expenses(846M)(683M)(196M)(353M)(586M)
Income Before Tax1.08B1.14B1.99B2.28B3.39B
Pre-Tax Margin9.1%9.0%13.9%13.6%16.9%
Income Tax Expense36M443M393M436M493M
Net Income1.04B698M1.59B1.85B2.89B
Net Margin8.7%5.5%11.2%11.1%14.4%
EPS (Basic)0.690.451.081.261.96
EPS (Diluted)0.690.451.071.251.94
Weighted Avg Shares1.42B1.43B1.45B1.47B1.48B
Weighted Avg Shares (Diluted)1.43B1.44B1.46B1.49B1.49B

Boston Scientific Corporation

NYSE:BSX

Intrinsic Alpha fair value

Locked

Current Price

$43.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.